Skip to Main Content

Pathology Research Faculty

  • Demetrios Braddock

    Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes regulating hemostasis, bone mineralization, and vascular development. These studies have progressed to the development of biologic therapeutics for vascular calcification disorders.

  • Robert Camp

    My primary activities involve teaching students at Yale School of Medicine, with an emphasis on curriculum development and the application of new technologies for instruction.

  • Jose Costa

    José Costa, MD, FACP, is Professor Emeritus of Pathology at Yale University School of Medicine and Professeur Honoraire at the University of Lausanne Switzerland. Dr. Costa is an internationally renowned leader in the field of diagnostics of cancer and pathogenesis of tumor formation. Having contributed to the transition from opinion-based medicine to evidence-based diagnosis he is now making use of novel tools to practice integrative systems pathology, an approach that strives to enable a personalized, predictive and precise diagnosis.

    Prior his transition to Emeritus status April first 2018 at the Yale School of Medicine, Dr Costa served in several positions of leadership that include: Chief of the Anatomical Pathology Branch at the Clinical Center, NIH Bethesda Md (1980-83); Director of the Institute of Pathology, University of Lausanne, Lausanne, Switzerland (1983-1993); President of the Board of Directors of the Centre Pluridisciplinaire d’Oncologie, Lausanne Switzerland (1985-1992); Director of Anatomical Pathology Yale New-Haven Hospital (1993-2007); and Deputy Director of the Yale Comprehensive Cancer Center (1995-2007). He is a sought after advisor to several academic, research and health organizations has served or currently serves as board member or advisor to several institutions including the ISREC (Swiss Cancer Research Institut); the Ludwig Institut Branch in Lausanne; the Deutsche Krebs Forshung Zenter (Heidelberg); the Institut of Molecular Pathology at Porto (Portugal); The Catalan Institut of Oncology [ICO] Barcelona, Spain; the Centro Nacional de Investigacion en Oncologia[CNIO] Madrid,Spain, the Instituto Carlos III, Madrid, Spain, the Center for Virtual Tumor Modeling (Harvard); the NIH Consensus Pannels and the NCI’s EDRN in Bethesda, MD, USA.

    Throughout his career Dr. Costa has integrated advances in basic understanding of cancer to the clinical area of diagnosis, prognosis and early detection. He has contributed over 170 original publications to the technical literature, and is among a small group of investigators using evolutionary and ecological theory to predict tumor behavior. His laboratory investigates the micro-evolutionary dynamics involved in tumor formation and tumor progression using both experimental and theoretical modeling at the systems level. This work has identified novel and promising ways to detect early cancer and ways to follow the changes in tumors under therapy. Dr. Costa is co-inventor of two novel diagnostic technologies and has served in the oversight board of Yale’s Office of Cooperative Research. He has also been involved in the crafting of public-private joint ventures in Switzerland (IP-AMS Labs [1999]), the early launching of Curagen Corporation (New Haven, CT [1996]), the founding of Aureon Biosciences (Yonkers, NY [2001]), VCN (Barcelona, Spain [2005]), and PetaOmics (San Marcos, TX [2014]).

    The contributions of Dr Costa have been recognized by several awards including a Special Achievement Award from NIH, election as a Fellow to the American Association for the Advancement of Science (2003); the Gold Medal of the International Academy of Pathology and the Trueta Medal from the Catalan government for contributions to public health.

    A firm believer in the dynamics coming from multi-disciplinarity and cooperation, Dr Costa continues to create an environment that will transform health care and set the standards for the 21st century. He is particularly interested in exploring synergies between academia, private industry, and governmental programs.

  • Karin Finberg

    Karin Finberg received her B.S., M.D., and Ph.D. degrees from Yale. Her Ph.D. dissertation with Dr. Richard Lifton in the Department of Genetics focused on the genetic basis of an autosomal recessive disorder of systemic pH homeostasis, distal renal tubular acidosis with sensorineural deafness. After graduating from Yale, Karin completed residency training in Clinical Pathology at Massachusetts General Hospital and clinical fellowship training in the Harvard Medical School Molecular Genetic Pathology Training Program based at Brigham and Women’s Hospital. She then completed postdoctoral research training in the laboratory of Dr. Nancy Andrews, first at Children’s Hospital Boston and later at Duke University Medical Center, where she employed genetic study of patients with an inherited form of iron deficiency anemia to shed insight into mechanisms of systemic iron regulation. In her research laboratory at Yale, Karin continues to investigate mechanisms of iron balance through genetic study of patients with iron-related phenotypes and through characterization of genetically targeted mouse models. She also contributes to patient care as a molecular genetic pathologist in the Molecular Diagnostics Unit of the Department of Pathology.

  • Peter Gershkovich

    Dr. Peter Gershkovich received his medical degree from the Altay State Medical Institute, Barnaul, Russia. After graduation, he remained in his alma mater, getting a prestigious position as an assistant professor the Department of Physiology where he developed strong interest in information technology and its practical applications for the computerized assessment of cardiac and respiratory function. After immigrating to the US at the end of 1993 and receiving Master’s degree in Health Administration from Suffolk University, Boston he worked as a professional programmer in the field of medicine for several years. In 2000 he was accepted into the Medical Informatics Fellowship at Yale Center for Medical Informatics where he continued learning software development focusing on genomic data analysis, automation of clinical guidelines, and information visualization. 

    Shortly after finishing the fellowship program, Dr. Gershkovich joined the Informatics team at Yale Medical School Pathology Department.  He is currently a Research Scientist and the Director of Pathology Informatics at Yale Medical School.

    Dr. Gershkovich has more than twenty years of experience in medical software development. Combining his knowledge of medicine and programming over the past fourteen years with Yale Medical School Pathology Department, Dr. Gershkovich has been studying methods of agile software development to rapidly close the functionality gaps that exist between emerging technologies and commercial Laboratory Information Systems (LIS). He developed a range of cutting-edge software applications that bridged research and clinical operations. Dr. Gershkovich remains interested in clinical information visualization, DNA sequencing analysis, NLP, and full-text search of clinical data.

  • Pallavi Gopal

    Pallavi Gopal is a graduate of the Medical Scientist Training Program at the University of Pennsylvania, Perelman School of Medicine in Philadelphia. Her Ph.D. thesis work in Neuroscience with Dr. Jeffrey Golden focused on understanding the cellular and molecular mechanisms that guide neuronal migration during forebrain development. After earning her M.D., Pallavi completed postgraduate clinical training in Anatomic Pathology and Neuropathology at the Hospital of the University of Pennsylvania. She did her postdoctoral research training with Dr. Erika Holzbaur at the University of Pennsylvania. Dr. Gopal is a recipient of the NINDS Clinical Scientist Research Career Development Award. She joined the Pathology Department at Yale School of Medicine in January 2018.

    The Gopal lab is broadly interested in mRNA transport, RNA metabolism and its regulation in healthy and diseased neurons. As a physician-scientist, Dr. Gopal’s research aims to bridge neuronal cell biology and neuropathology of neurodegenerative disease. Her post-doctoral research provided new insight into the biophysical properties of neuronal ribonucleoprotein (RNP) granules and has shown that ALS-linked mutations fundamentally perturb the dynamic properties and transport of neuronal RNP complexes. The focus of the Gopal lab is to elucidate the molecular mechanisms driving neuronal RNP granule assembly, the spatiotemporal maturation and function of diverse RNP granules in neuronal physiology, and pathologic transitions in disease.

  • Robert Homer

    My major interests are in diagnostic and experimental lung pathology.

    I entered the MD-PhD program at Yale School of Medicine in 1979. My PhD with Donal Murphy described a novel antigenic structure within the murine MHC. Upon graduation I trained in Anatomic Pathology under the supervision of Dr. Juan Rosai and simultaneously completed a post-doctoral fellowship with Richard Flavell, chair of the section of immunobiology, with a focus on T cell tolerance.

    For many years, I worked on various murine models of inflammatory lung disease, ran an NIH funded morphology core for the Yale pulmonary section and ran a laboratory at West Haven VA looking at murine models of pulmonary fibrosis. I now still consult on various experimental models of lung disease and work with collaborators analyzing human fibrotic and neoplastic disease.

    I am heavily involved in medical school curriculum development as Director of Medical Studies for Pathology, am on the curriculum committee and am Co-Director of one of the new master courses for the new (starting 2015) pre-clinical curriculum for YSM.

    I have been Director of Anatomic Pathology at West Haven VA since 1994. I have been lead thoracic pathologist at Yale since 2004.

  • Stanley Hudnall

    Dr. Hudnall is an AP/CP board certified hematopathologist with a special interest in lymphoproliferative disorders and the role of chronic imflammation and tumor-infiltrating lymphocytes and monocytes in tumor progression. Dr. Hudnall is also interested in the role of infectious agents in lymphoproliferative disorders, with a special interest in herpes viruses.

  • Pei Hui

    Dr. Hui is Professor in the Department of Pathology and Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. He received combined anatomic and clinical pathology residency training at Yale-New Haven Hospital in 2000, followed by Oncological Pathology Fellowship training at MSKCC. He joined the pathology faculty at Yale in 2001 and became full professor in 2013. Dr. Hui is a board certified surgical pathologist with clinical specialty areas including gynecologic pathology and molecular diagnostics. Currently, he is Director of Gynecologic Pathology Service, Clinical director of the Molecular Diagnostics Laboratory and Director of Gynecologic Pathology Fellowship Program.

    Dr. Hui oversees a dynamic, high volume gynecologic pathology service at Yale. One of his long-term academic goals is to build an outstanding gynecological pathology program with emphasis on diagnostic tissue evaluation, oncological biomarker identification and clinical applications, and understanding the pathogenesis of various gynecological cancers. Dr. Hui has particular clinical expertise in the diagnostic workup of gestational trophoblastic disease. He serves on the editorial boards of International Journal of Gynecological Pathology, Human Pathology, American Journal of Clinical Pathology and Journal of Clinical Pathology. He has authored over 190 publications and written three pathology textbooks including Cytology and Surgical Pathology of Gynecologic Neoplasms, Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology, and Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology. Dr. Hui was a member of the consensus and editorial working group for the 2014 WHO Blue Book of tumor classifications of female reproductive organs and is the responsible author for the WHO classification of gestational trophoblastic disease. Dr. Hui serves on the Board of Directors of the International Society of Gynecological Pathologists (ISGyP) since 2015 and is currently treasurer of the society.


  • Michael Kashgarian

    Michael Kashgarian is professor emeritus of and senior research scientist in pathology. He received his medical degree from Yale School of Medicine in 1958, completed his residency in pathology at the Yale-New Haven Medical Center in 1963, and completed a fellowship in laboratory medicine at Yale-New Haven Hospital in 1964. While on the Yale faculty he established a diagnostic renal pathology and electron microscopy laboratory that bears his name. He was also a pioneer in understanding the process of organ rejection. Although Kashgarian has retired, he continues to be active in the diagnosis of renal and cardiac biopsies.

  • Samuel Katz

    Samuel G. Katz graduated with a combined B.S./M.S. from Yale University in 1995. He then pursued dual M.D., Ph.D. training in the Health Sciences & Technology (HST) program jointly administered by MIT and Harvard. His Ph.D. thesis with Stuart H. Orkin focused on the transcriptional regulation of hematopoiesis. Sam then completed a residency in pathology and fellowship in hematopathology at Brigham and Women’s Hospital. He performed his post-doctoral studies on apoptosis with Loren D. Walensky at the Dana Farber Cancer Institute. As an Associate Professor of Pathology at Yale University, Dr. Katz manages a laboratory concentrating on both intrinsic mechanisms of cell death and ways to reprogram immunocytes to mediate the extrinsic program of cell death, as well as contributes to patient care as an active hematopathologist.

  • Steven Kleinstein

    Dr. Steven Kleinstein is a computational immunologist with a combination of "big data" analysis and immunology domain expertise. His research interests include both developing new computational methods and applying these methods to study human immune responses. Dr. Kleinstein received a B.A.S. in Computer Science from the University of Pennsylvania and a Ph.D. in Computer Science from Princeton University. He is currently Professor of Pathology (with a secondary appointment in Immunobiology) at the Yale School of Medicine, and a member of the Interdepartmental Program in Computational Biology and Bioinformatics (CBB), and the Human and Translational Immunology Program. 

    Specific areas of research focus include:

    • High-throughput B cell receptor (BCR) repertoire profiling (AIRR-seq or Rep-seq)
    • Immune signatures of human infection and vaccination responses


  • Themis Kyriakides

    Dr. Kyriakides completed a PhD at Washington State University in 1993. He did a postdoctoral fellowship at the University of Washington. His lab at Yale studies the  the foreign body response to biomaterials and nanomaterials. In addition, Dr. Kyriakides studies nanomaterials and cell interactions with a focus on biosensing. Finally, ongoing efforts in the lab include engineering of tissue constructs to stimulate healing in mouse models of diabetes. He is Director of Graduate Studies for the Experimental Pathology PhD program. He also serves as a mentor for students from the School of Engineering and Applied Science.

  • Morgan Levine

    Morgan Levine is a ladder-rank Assistant Professor in the Department of Pathology at the Yale School of Medicine and a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging. Her work relies on an interdisciplinary approach, integrating theories and methods from statistical genetics, computational biology, and mathematical demography to develop biomarkers of aging for humans and animal models using high-dimensional omics data. As PI or co-Investigator on multiple NIH-, Foundation-, and University-funded projects, she has extensive experience using systems-level and machine learning approaches to track epigenetic, transcriptomic, and proteomic changes with aging and incorporate this information to develop measures of risk stratification for major chronic diseases, such as cancer and Alzheimer’s disease. Her work also involves development of systems-level outcome measures of aging, aimed at facilitating evaluation for Geroprotective Interventions. A number of the existing biological aging measures she has developed are being applied in both basic and observational research.

  • Zachary Levine

    Zachary (Zach) Levine is currently an Assistant Professor of Pathology at the Yale School of Medicine and the Graduate School at Yale University. His training is in computational biophysics and his interests have recently expanded into solution biophysics techniques in amyloid protein systems. Many of his projects combine atomistic models with solution NMR spectroscopy in order to better understand the physical and thermodynamic determinants of age-related diseases.

    In particular, we work to understand protein aggregation diseases from a biophysical perspective. Many of these conditions involve a toxic accumulation of amyloid proteins and plaques over the lifecourse, leading to degenerative dysfunction and death. By combining molecular models of protein folding and aggregation with solution biophysics techniques, we can deduce and modify thermodynamic landscapes that are distinctly pathological in order to mitigate human diseases.